US vaccine company Gritstone bio closed 62% lower after Tuesday’s trading after releasing disappointing news.
The Californian company earlier provided interim Phase II data an ongoing study evaluating GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer (MSS-CRC).
This randomized, controlled study is designed to evaluate the clinical benefit of maintenance therapy with GRANITE in combination with immune checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab, versus fluoropyrimidine/bevacizumab alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze